- 专利标题： COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR
-
申请号： PCT/IB2021/055548申请日： 2021-06-23
-
公开(公告)号： WO2021260579A1公开(公告)日： 2021-12-30
- 发明人: METTETAL II, Jerome Thomas , DURANT, Stephen Thomas , ASTANEH, Azadeh Cheraghchi Bashi , LAU, Alan Yin Kai , WALLEZ, Yann
- 申请人： ASTRAZENECA UK LIMITED , DAIICHI SANKYO COMPANY, LIMITED
- 申请人地址： 1 Francis Crick Avenue; 3-5-1, Nihonbashi Honcho
- 专利权人： ASTRAZENECA UK LIMITED,DAIICHI SANKYO COMPANY, LIMITED
- 当前专利权人： ASTRAZENECA UK LIMITED,DAIICHI SANKYO COMPANY, LIMITED
- 当前专利权人地址： 1 Francis Crick Avenue; 3-5-1, Nihonbashi Honcho
- 代理机构： FAIRBAIRN, Angus Chisholm
- 优先权： US63/043,498 2020-06-24
- 主分类号： A61K47/68
- IPC分类号： A61K47/68 ; A61K31/5377 ; A61K45/06 ; A61P35/00 ; A61K47/6803 ; A61K47/6855 ; A61K47/6889 ; C07K16/32 ; C07K2317/24
摘要：
A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I):
IPC分类:
